Project Name: Collaborative Working- Novartis Re-imagining Care Pathways Collaborative Working Project for Norfolk and Norwich University Hospitals NHS Foundation Trust Heart Failure Service
Project Summary:
The Reimagining Care Pathways CWP is a service offered by Novartis, which comprises a series of workshops, with the aim of providing pathway mapping support to the CW Partner (healthcare and service teams) to:
- Improve efficiency and service effectiveness for the benefit of patient care.
- Address the local challenges they face in the delivery of patient care.
The programme facilitates area teams (Trust or ICS) to identify areas for efficiency within their service for prioritisation. The programme will be carried out in a number of different institutions. The service is facilitated by the Novartis Solutions Implementation Manager (SIM) Team.
Planned Milestones:
| Milestone Description | Milestone Delivery Date | Milestone Evidence | |
|---|---|---|---|
| 1 | SIM & CW Partner’s key stakeholders: Both parties agree the scope of the NRCP CWP and arrange the dates for the stakeholder’s interviews. | Execution of collaborative working agreement (CWA) date +4 weeks | SIM: Meeting minutes |
| 2 | SIM & CW Partner: | Execution of collaborative working agreement (CWA) date +8 weeks | SIM: Meeting minutes |
| 3 | SIM & CW Partner: Mapping the Pathway – Workshop (as a guide, circa 2 weeks from the last interview) | Execution of collaborative working agreement (CWA) date +10 weeks | SIM: Pathway Map |
| 4 | SIM & CW Partner: Feedback/Consultation with NHS post workshop (as a guide, no later than +4 weeks from workshop) | Execution of collaborative working agreement (CWA) date +14 weeks | SIM: Final Pathway Map Report detailing any identified any unmet needs / efficiency constraints in their service. SIM: Meeting minutes |
Expected Benefits:
Anticipated benefits for patients:
We anticipate that some of the benefits for patients could include;
Potentially fewer visits and shorter waiting times as a result of a more efficient clinical pathway
Faster and more equitable access to the complete range of NICE approved treatment options.
Anticipated benefits to the CW Partner:
Improved understanding of the current service pathway, and associated efficiencies and inefficiencies. Potential to lead to solutions which could allow the CW Partner’s organisation to enhance both patient experience and outcomes.
Anticipated benefits to Novartis:
Understanding of possible opportunities to partner with the CW Partner to enhance patient outcomes and experience. Better understanding of patients,’ carers and customers’ needs, which may inform future service offerings, and synergies between needs of the customer and value of Novartis offerings.
Start Date & Duration: 9th May 2024, 14 weeks
UK2401197658